Scott N. Braunstein M.D.
Net Worth
Last updated:
What is Scott N. Braunstein M.D. net worth?
The estimated net worth of Dr. Scott N. Braunstein M.D. is at least $5,695,457 as of 27 Mar 2024. He owns shares worth $122,876 as insider, has earned $179,301 from insider trading and has received compensation worth at least $5,393,280 in Marinus Pharmaceuticals, Inc..
What is the salary of Scott N. Braunstein M.D.?
Dr. Scott N. Braunstein M.D. salary is $898,880 per year as Chief Executive Officer, Pres & Director in Marinus Pharmaceuticals, Inc..
How old is Scott N. Braunstein M.D.?
Dr. Scott N. Braunstein M.D. is 62 years old, born in 1963.
What stocks does Scott N. Braunstein M.D. currently own?
As insider, Dr. Scott N. Braunstein M.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Marinus Pharmaceuticals, Inc. (MRNS) | Chief Executive Officer, Pres & Director | 223,512 | $0.55 | $122,876 |
What does Marinus Pharmaceuticals, Inc. do?
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Scott N. Braunstein M.D. insider trading
Marinus Pharmaceuticals, Inc.
Dr. Scott N. Braunstein M.D. has made 3 insider trades between 2019-2024, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 100,000 units of MRNS stock on 13 Dec 2019. As of 27 Mar 2024 he still owns at least 223,512 units of MRNS stock.
Marinus Pharmaceuticals key executives
Marinus Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Joseph Hulihan M.D. (69) Chief Medical Officer
- Dr. Scott N. Braunstein M.D. (62) Chief Executive Officer, Pres & Director